Potential of novel Mycobacterium tuberculosis infection phase-dependent antigens in the diagnosis of TB disease in a high burden setting

BMC Infectious Diseases

Volumn 12, Issue , 2012, Pages

  Chegou, Novel N ^a   Black, Gillian F ^a   Loxton, Andre G ^a   Stanley, Kim ^a   Essone, Paulin N ^a   Klein, Michel R ^b   Parida, Shreemanta K ^c   Kaufmann, Stefan H E ^c   Doherty, T Mark ^d,e   Friggen, Annemieke H ^b   Franken, Kees L ^b   Ottenhoff, Tom H ^b   Walzl, Gerhard ^a  

^a UNIVERSITY OF STELLENBOSCH   (South Africa)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c MAX PLANCK INSTITUTE FOR INFECTION BIOLOGY   (Germany)

^d STATENS SERUM INSTITUT   (Denmark)

^e GLAXOSMITHKLINE   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CULTURE FILTRATE PROTEIN 10; EARLY SECRETORY ANTIGENIC TARGET 6; GAMMA INTERFERON; MYCOBACTERIUM ANTIGEN; BACTERIAL ANTIGEN;

ADULT; ARTICLE; BLOOD CULTURE; CYTOKINE PRODUCTION; CYTOKINE RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; REGULON; SERODIAGNOSIS; SOUTH AFRICA; VALIDATION STUDY; CELL CULTURE; EVALUATION; IMMUNOLOGY; ISOLATION AND PURIFICATION; MIDDLE AGED; MONONUCLEAR CELL; MYCOBACTERIUM TUBERCULOSIS; SECRETION; SENSITIVITY AND SPECIFICITY; TUBERCULOSIS;

ADULT; ANTIGENS, BACTERIAL; CELLS, CULTURED; FEMALE; HUMANS; INTERFERON-GAMMA; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; SENSITIVITY AND SPECIFICITY; SOUTH AFRICA; TUBERCULOSIS;

EID: 84856004776     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-12-10     Document Type: Article

References (62)

1. Chegou NN, Hoek KG, Kriel M, Warren RM, Victor TC, Walzl G. Tuberculosis assays: past, present and future. Expert Rev Anti Infect Ther 2011, 9:457-469. 10.1586/eri.11.23, 21504402.
2. Boehme CC, Nabeta P, Hillemann D, Nicol M, Shenai S, Krapp F, et al. Rapid Molecular Detection of Tuberculosis and Rifampicin Resistance. N Engl J Med 2010, 363:1070-1081. 10.1056/NEJMe1008496, 20825320.
3. WHO REPORT 2009. Global Tuberculosis Control: Epidemiology, Strategy, Financing. , http://www.who.int/tb/publications/global_report/2009/pdf/full_report.pdf
4. Munk ME, Arend SM, Brock I, Ottenhoff TH, Andersen P. Use of ESAT-6 and CFP-10 antigens for diagnosis of extrapulmonary tuberculosis. J Infect Dis 2001, 183:175-176. 10.1086/317663, 11106545.
5. Hesseling AC, Mandalakas AM, Kirchner HL, Chegou NN, Marais BJ, Stanley K, et al. Highly discordant T cell responses in individuals with recent exposure to household tuberculosis. Thorax 2009, 64:840-846. 10.1136/thx.2007.085340, 18682523.
6. Mandalakas AM, Hesseling AC, Chegou NN, Kirchner HL, Zhu X, Marais BJ, et al. High level of discordant IGRA results in HIV-infected adults and children. Int J Tuberc Lung Dis 2008, 12:417-423.
7. Diel R, Goletti D, Ferrara G, Bothamley G, Cirillo D, Kampmann B, et al. Interferon-gamma release assays for the diagnosis of latent Mycobacterium tuberculosis infection: a systematic review and meta-analysis. Eur Respir J 2011, 37:88-99. 10.1183/09031936.00115110, 21030451.
8. Demissie A, Leyten EM, Abebe M, Wassie L, Aseffa A, Abate G, et al. Recognition of stage-specific mycobacterial antigens differentiates between acute and latent infections with Mycobacterium tuberculosis. Clin Vaccine Immunol 2006, 13:179-186. 10.1128/CVI.13.2.179-186.2006, 1391929, 16467323.
9. Honer zu BK, Russell DG. Mycobacterial persistence: adaptation to a changing environment. Trends Microbiol 2001, 9:597-605. 10.1016/S0966-842X(01)02238-7, 11728873.
10. Zvi A, Ariel N, Fulkerson J, Sadoff JC, Shafferman A. Whole genome identification of Mycobacterium tuberculosis vaccine candidates by comprehensive data mining and bioinformatic analyses. BMC Med Genomics 2008, 1:18. 10.1186/1755-8794-1-18, 2442614, 18505592.
11. Mukamolova GV, Kaprelyants AS, Young DI, Kell DB. A bacterial cytokine. Proc Natl Acad Sci 1998, 95:8916-8921. 10.1073/pnas.95.15.8916, 21177, 9671779.
12. Franken KL, Hiemstra HS, van Meijgaarden KE, Subronto Y, den HJ, Ottenhoff TH, et al. Purification of his-tagged proteins by immobilized chelate affinity chromatography: the benefits from the use of organic solvent. Protein Expr Purif 2000, 18:95-99. 10.1006/prep.1999.1162, 10648174.
13. Black GF, Thiel BA, Ota MO, Parida SK, Adegbola R, Boom WH, et al. Immunogenicity of novel DosR regulon-encoded candidate antigens of Mycobacterium tuberculosis in three high-burden populations in Africa. Clin Vaccine Immunol 2009, 16:1203-1212. 10.1128/CVI.00111-09, 2725533, 19553548.
14. Black GF, Fine PEM, Warndorff DK, Floyd S, Weir RE, Blackwell JM, et al. Relationship between IFN-gamma and skin test responsiveness to Mycobacterium tuberculosis PPD in healthy, non-BCG-vaccinated young adults in Northern Malawi. Int J Tuberc Lung Dis 2001, 5:664-672.
15. Weir RE, Brennan PJ, Butlin CR, Dockrell HM. Use of a whole blood assay to evaluate in vitro T cell responses to new leprosy skin test antigens in leprosy patients and healthy subjects. Clin Exp Immunol 1999, 116:263-269. 10.1046/j.1365-2249.1999.00892.x, 1905275, 10337017.
16. Desem N, Jones SL. Development of a human gamma interferon enzyme immunoassay and comparison with tuberculin skin testing for detection of Mycobacterium tuberculosis infection. Clin Diagn Lab Immunol 1998, 5:531-536. 95613, 9665962.
17. Chegou NN, Black GF, Kidd M, van Helden PD, Walzl G. Host markers in Quantiferon supernatants differentiate active TB from latent TB infection: preliminary report. BMC Pulm Med 2009, 9:21. 10.1186/1471-2466-9-21, 2696407, 19445695.
18. Sahiratmadja E, Alisjahbana B, de BT, Adnan I, Maya A, Danusantoso H, et al. Dynamic changes in pro- and anti-inflammatory cytokine profiles and gamma interferon receptor signaling integrity correlate with tuberculosis disease activity and response to curative treatment. Infect Immun 2007, 75:820-829. 10.1128/IAI.00602-06, 1828524, 17145950.
19. Leyten EM, Lin MY, Franken KL, Friggen AH, Prins C, van Meijgaarden KE, et al. Human T-cell responses to 25 novel antigens encoded by genes of the dormancy regulon of Mycobacterium tuberculosis. Microbes Infect 2006, 8:2052-2060. 10.1016/j.micinf.2006.03.018, 16931093.
20. Commandeur S, Lin MY, van Meijgaarden KE, Friggen AH, Franken KL, Drijfhout JW, et al. Double- and monofunctional CD4(+) and CD8(+) T-cell responses to Mycobacterium tuberculosis DosR antigens and peptides in long-term latently infected individuals. Eur J Immunol
21. Schuck SD, Mueller H, Kunitz F, Neher A, Hoffmann H, Franken KL, et al. Identification of T-cell antigens specific for latent mycobacterium tuberculosis infection. PLoS One 2009, 4:e5590. 10.1371/journal.pone.0005590, 2680040, 19440342.
22. Schnappinger D, Ehrt S, Voskuil MI, Liu Y, Mangan JA, Monahan IM, et al. Transcriptional Adaptation of Mycobacterium tuberculosis within Macrophages: Insights into the Phagosomal Environment. J Exp Med 2003, 198:693-704. 10.1084/jem.20030846, 2194186, 12953091.
23. Friedland JS, Shattock R, Remick DG, Griffin GE. Mycobacterial 65-kD heat shock protein induces release of proinflammatory cytokines from human monocytic cells. Clin Exp Immunol 1993, 91:58-62. 1554637, 8419086.
24. Lewthwaite JC, Coates AR, Tormay P, Singh M, Mascagni P, Poole S, et al. Mycobacterium tuberculosis chaperonin 60.1 is a more potent cytokine stimulator than chaperonin 60.2 (Hsp 65) and contains a CD14-binding domain. Infect Immun 2001, 69:7349-7355. 10.1128/IAI.69.12.7349-7355.2001, 98821, 11705907.
25. Geluk A, Lin MY, van Meijgaarden KE, Leyten EM, Franken KL, Ottenhoff TH, et al. T-Cell Recognition of the HspX Protein of Mycobacterium tuberculosis Correlates with Latent M. tuberculosis Infection but Not with M. bovis BCG Vaccination. Infect Immun 2007, 75:2914-2921. 10.1128/IAI.01990-06, 1932904, 17387166.
26. Antas PR, Cardoso FL, Pereira KC, Franken KL, Cunha KS, Klatser P, et al. T cell immune responses to mycobacterial antigens in Brazilian tuberculosis patients and controls. Trans R Soc Trop Med Hyg 2005, 99:699-707. 10.1016/j.trstmh.2005.05.002, 15993451.
27. Skjot RL, Oettinger T, Rosenkrands I, Ravn P, Brock I, Jacobsen S, et al. Comparative evaluation of low-molecular-mass proteins from Mycobacterium tuberculosis identifies members of the ESAT-6 family as immunodominant T-cell antigens. Infect Immun 2000, 68:214-220. 10.1128/IAI.68.1.214-220.2000, 97123, 10603390.
28. Skjot RL, Brock I, Arend SM, Munk ME, Theisen M, Ottenhoff TH, et al. Epitope mapping of the immunodominant antigen TB10.4 and the two homologous proteins TB10.3 and TB12.9, which constitute a subfamily of the esat-6 gene family. Infect Immun 2002, 70:5446-5453. 10.1128/IAI.70.10.5446-5453.2002, 128304, 12228269.
29. Wang LM, Bai YL, Shi CH, Gao H, Xue Y, Jiang H, et al. Immunogenicity and protective efficacy of a DNA vaccine encoding the fusion protein of mycobacterium heat shock protein 65 (Hsp65) with human interleukin-2 against Mycobacterium tuberculosis in BALB/c mice. APMIS 2008, 116:1071-1081. 10.1111/j.1600-0463.2008.01095.x, 19133010.
30. Shi C, Yuan S, Zhang H, Zhang T, Wang L, Xu Z. Cell-mediated immune responses and protective efficacy against infection with Mycobacterium tuberculosis induced by Hsp65 and hIL-2 fusion protein in mice. Scand J Immunol 2009, 69:140-149. 10.1111/j.1365-3083.2008.02207.x, 19144078.
31. Palma C, Iona E, Giannoni F, Pardini M, Brunori L, Orefici G, et al. The Ag85B protein of Mycobacterium tuberculosis may turn a protective immune response induced by Ag85B-DNA vaccine into a potent but non-protective Th1 immune response in mice. Cell Microbiol 2007, 9:1455-1465. 10.1111/j.1462-5822.2007.00884.x, 17250590.
32. Palma C, Iona E, Giannoni F, Pardini M, Brunori L, Fattorini L, et al. The LTK63 adjuvant improves protection conferred by Ag85B DNA-protein prime-boosting vaccination against Mycobacterium tuberculosis infection by dampening IFN-gamma response. Vaccine 2008, 26:4237-4243. 10.1016/j.vaccine.2008.05.050, 18584925.
33. Forbes EK, Sander C, Ronan EO, McShane H, Hill AV, Beverley PC, et al. Multifunctional, high-level cytokine-producing Th1 cells in the lung, but not spleen, correlate with protection against Mycobacterium tuberculosis aerosol challenge in mice. J Immunol 2008, 181:4955-4964. 2867031, 18802099.
34. Tchilian EZ, Desel C, Forbes EK, Bandermann S, Sander CR, Hill AV, et al. Immunogenicity and protective efficacy of prime-boost regimens with recombinant (delta)ureC hly+ Mycobacterium bovis BCG and modified vaccinia virus ankara expressing M. tuberculosis antigen 85A against murine tuberculosis. Infect Immun 2009, 77:622-631. 10.1128/IAI.00685-08, 2632018, 19064635.
35. Brookes RH, Hill PC, Owiafe PK, Ibanga HB, Jeffries DJ, Donkor SA, et al. Safety and immunogenicity of the candidate tuberculosis vaccine MVA85A in West Africa. PLoS One 2008, 3:e2921. 10.1371/journal.pone.0002921, 2488375, 18698342.
36. Hawkridge T, Scriba TJ, Gelderbloem S, Smit E, Tameris M, Moyo S, et al. Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in healthy adults in South Africa. J Infect Dis 2008, 198:544-552. 10.1086/590185, 2822902, 18582195.
37. Pardini M, Giannoni F, Palma C, Iona E, Cafaro A, Brunori L, et al. Immune response and protection by DNA vaccines expressing antigen 85B of Mycobacterium tuberculosis. FEMS Microbiol Lett 2006, 262:210-215. 10.1111/j.1574-6968.2006.00390.x, 16923077.
38. Dietrich J, Aagaard C, Leah R, Olsen AW, Stryhn A, Doherty TM, et al. Exchanging ESAT6 with TB10.4 in an Ag85B fusion molecule-based tuberculosis subunit vaccine: efficient protection and ESAT6-based sensitive monitoring of vaccine efficacy. J Immunol 2005, 174:6332-6339.
39. Hervas-Stubbs S, Majlessi L, Simsova M, Morova J, Rojas MJ, Nouze C, et al. High frequency of CD4+ T cells specific for the TB10.4 protein correlates with protection against Mycobacterium tuberculosis infection. Infect Immun 2006, 74:3396-3407. 10.1128/IAI.02086-05, 1479244, 16714570.
40. Kumar G, Dagur PK, Singh M, Yadav VS, Dayal R, Singh HB, et al. Diagnostic potential of Ag85C in comparison to various secretory antigens for childhood tuberculosis. Scand J Immunol 2008, 68:177-183. 10.1111/j.1365-3083.2008.02133.x, 18702747.
41. Rajan AN, Kashyap RS, Purohit HJ, Taori GM, Daginawala HF. Serodiagnosis of tuberculosis based on the analysis of the 65 kD heat shock protein of Mycobacterium tuberculosis. Int J Tuberc Lung Dis 2007, 11:792-797.
42. Mudaliar AV, Kashyap RS, Purohit HJ, Taori GM, Daginawala HF. Detection of 65 kD heat shock protein in cerebrospinal fluid of tuberculous meningitis patients. BMC Neurol 2006, 6:34. 10.1186/1471-2377-6-34, 1578580, 16978411.
43. Connell TG, Shey MS, Seldon R, Rangaka MX, van CG, Simsova M, et al. Enhanced ex vivo stimulation of Mycobacterium tuberculosis-specific T cells in human immunodeficiency virus-infected persons via antigen delivery by the Bordetella pertussis adenylate cyclase vector. Clin Vaccine Immunol 2007, 14:847-854. 10.1128/CVI.00041-07, 1951068, 17522328.
44. Feske M, Nudelman RJ, Medina M, Lew J, Singh M, Couturier J, et al. Enhancement of human antigen-specific memory T-cell responses by interleukin-7 may improve accuracy in diagnosing tuberculosis. Clin Vaccine Immunol 2008, 15:1616-1622. 10.1128/CVI.00185-08, 2565935, 18753334.
45. Geluk A, van der Ploeg-van Schip JJ, van Meijgaarden KE, Commandeur S, Drijfhout JW, Benckhuijsen WE, et al. Enhancing sensitivity of detection of immune responses to Mycobacterium leprae peptides in whole-blood assays. Clin Vaccine Immunol 2010, 17:993-1004. 10.1128/CVI.00046-10, 2884434, 20427628.
46. World Health Organisation. WHO warns against the use of inaccurate blood tests for active tuberculosis. , http://www.who.int/mediacentre/news/releases/2011/tb_20110720/en/index.html
47. Honaker RW, Stewart A, Schittone S, Izzo A, Klein MR, Voskuil MI. Mycobacterium bovis BCG vaccine strains lack narK2 and narX induction and exhibit altered phenotypes during dormancy. Infect Immun 2008, 76:2587-2593. 10.1128/IAI.01235-07, 2423053, 18362135.
48. Wayne LG, Sohaskey CD. Nonreplicating persistence of mycobacterium tuberculosis. Annu Rev Microbiol 2001, 55:139-163. 10.1146/annurev.micro.55.1.139, 11544352.
49. Lin MY, Ottenhoff TH. Not to wake a sleeping giant: new insights into host-pathogen interactions identify new targets for vaccination against latent Mycobacterium tuberculosis infection. Biol Chem 2008, 389:497-511. 10.1515/BC.2008.057, 18953716.
50. Roupie V, Romano M, Zhang L, Korf H, Lin MY, Franken KL, et al. Immunogenicity of eight dormancy regulon-encoded proteins of Mycobacterium tuberculosis in DNA-vaccinated and tuberculosis-infected mice. Infect Immun 2007, 75:941-949. 10.1128/IAI.01137-06, 1828490, 17145953.
51. Goletti D, Butera O, Vanini V, Lauria FN, Lange C, Franken KL, et al. Response to Rv2628 latency antigen associates with cured tuberculosis and remote infection. Eur Respir J 2010, 36:135-142. 10.1183/09031936.00140009, 19926735.
52. Chiacchio T, Petruccioli E, Vanini V, Butera O, Cuzzi G, Petrone L, et al. Higher frequency of T-Cell response to M. tuberculosis latency antigen Rv2628 at the site of active tuberculosis disease than in peripheral blood. PLoS One 2011, 6:e27539. 10.1371/journal.pone.0027539, 3213161, 22102905.
53. Wu X, Yang Y, Han Y, Zhang J, Liang Y, Li H, et al. Effect of recombinant Rv1009 protein on promoting the growth of Mycobacterium tuberculosis. J Appl Microbiol 2008, 105:1121-1127. 10.1111/j.1365-2672.2008.03850.x, 18843791.
54. Commandeur S, van Meijgaarden KE, Lin MY, Franken KL, Friggen AH, Drijfhout JW, et al. Identification of human T-cell responses to Mycobacterium tuberculosis resuscitation-promoting factors in long-term latently infected individuals. Clin Vaccine Immunol 2011, 18:676-683. 10.1128/CVI.00492-10, 3122556, 21248154.
55. Tufariello JM, Mi K, Xu J, Manabe YC, Kesavan AK, Drumm J, et al. Deletion of the Mycobacterium tuberculosis resuscitation-promoting factor Rv1009 gene results in delayed reactivation from chronic tuberculosis. Infect Immun 2006, 74:2985-2995. 10.1128/IAI.74.5.2985-2995.2006, 1459759, 16622237.
56. Hernandez-Pando R, Chacon-Salinas R, Serafin-Lopez J, Estrada I. Immunology, Pathogenesis, Virulence. Tuberculosis 2007: From Basic Science to Patient Care 2007, 157-206. Palomino JC, Leao SC, Ritacco V.
57. Kaufmann SH, Parida SK. Tuberculosis in Africa: learning from pathogenesis for biomarker identification. Cell Host Microbe 2008, 4:219-228. 10.1016/j.chom.2008.08.002, 18779048.
58. Young DB, Gideon HP, Wilkinson RJ. Eliminating latent tuberculosis. Trends Microbiol 2009, 17:183-188. 10.1016/j.tim.2009.02.005, 19375916.
59. Lin MY, Geluk A, Smith SG, Stewart AL, Friggen AH, Franken KL, et al. Lack of immune responses to Mycobacterium tuberculosis DosR regulon proteins following Mycobacterium bovis BCG vaccination. Infect Immun 2007, 75:3523-3530. 10.1128/IAI.01999-06, 1932964, 17502400.
60. Marais BJ, Rabie H, Cotton MF. TB and HIV in children - advances in prevention and management. Paediatr Respir Rev 2011, 12:39-45. 10.1016/j.prrv.2010.09.002, 21172674.
61. Shams H, Weis SE, Klucar P, Lalvani A, Moonan PK, Pogoda JM, et al. Enzyme-linked immunospot and tuberculin skin testing to detect latent tuberculosis infection. Am J Respir Crit Care Med 2005, 172:1161-1168. 10.1164/rccm.200505-748OC, 2718400, 16081545.
62. Walzl G, Ronacher K, Hanekom W, Scriba TJ, Zumla A. Immunological biomarkers of tuberculosis. Nat Rev Immunol 2011, 11:343-354. 10.1038/nri2960, 21475309.